"PTX 200 is one of the very few drugs that targets Akt."... and its no wonder looking at the diagram below, Dalts. We have a lot of "shots on goal" here too (to use one of SYC's own analogies)!!! And, PTX200 opens yet another door for OmniCAR... does it not?
Is it fair to assume that with the likelihood of positive data from the current PTX200 AML trials (highest dose), it will be ready to join the ranks of our in-house CarT therapies to be combined with OmniCAR to qualify for Phase 1 registration, @dalts66?
We have a lot of "shots on goal" here too (to use one of SYC's own analogies)!!! And, PTX200 opens yet another door for OmniCAR... does it not?
